PINC Quote, Financials, Valuation and Earnings

Cryo-Cell International has a net margin of -39.96% compared to Premier's net margin of 3.55%. Premier's return on equity of -0.24% beat Cryo-Cell International's return on equity of --.

Premier has a consensus price target of $19.79, signalling upside risk potential of 2.41%. On the other hand Cryo-Cell International has an analysts' consensus of $8.50 which suggests that it could grow by 53.15%. Given that Cryo-Cell International has higher upside potential than Premier, analysts believe Cryo-Cell International is more attractive than Premier.

Premier has a beta of 0.516, which suggesting that the stock is 48.448% less volatile than S&P 500. In comparison Cryo-Cell International has a beta of 0.607, suggesting its less volatile than the S&P 500 by 39.282%.

Premier has a quarterly dividend of $0.21 per share corresponding to a yield of 4.35%. Cryo-Cell International offers a yield of 9.01% to investors and pays a quarterly dividend of $0.25 per share. Premier pays 79.64% of its earnings as a dividend. Cryo-Cell International pays out 502.5% of its earnings as a dividend. Premier's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future, but Cryo-Cell International's is not.

Premier quarterly revenues are $240.3M, which are larger than Cryo-Cell International quarterly revenues of $8M. Premier's net income of -$96M is lower than Cryo-Cell International's net income of $282.9K. Notably, Premier's price-to-earnings ratio is 14.37x while Cryo-Cell International's PE ratio is 555.00x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Premier is 1.69x versus 1.41x for Cryo-Cell International. Usually stocks with elevated PS ratios are considered overvalued.

Evolent Health has a net margin of -39.96% compared to Premier's net margin of -3.53%. Premier's return on equity of -0.24% beat Evolent Health's return on equity of -5.92%.

Premier has a consensus price target of $19.79, signalling upside risk potential of 2.41%. On the other hand Evolent Health has an analysts' consensus of $15.25 which suggests that it could grow by 78.7%. Given that Evolent Health has higher upside potential than Premier, analysts believe Evolent Health is more attractive than Premier.

Premier has a beta of 0.516, which suggesting that the stock is 48.448% less volatile than S&P 500. In comparison Evolent Health has a beta of 1.199, suggesting its more volatile than the S&P 500 by 19.872%.

Premier has a quarterly dividend of $0.21 per share corresponding to a yield of 4.35%. Evolent Health offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Premier pays 79.64% of its earnings as a dividend. Evolent Health pays out -32.59% of its earnings as a dividend. Premier's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Premier quarterly revenues are $240.3M, which are smaller than Evolent Health quarterly revenues of $646.5M. Premier's net income of -$96M is lower than Evolent Health's net income of -$22.8M. Notably, Premier's price-to-earnings ratio is 14.37x while Evolent Health's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Premier is 1.69x versus 0.38x for Evolent Health. Usually stocks with elevated PS ratios are considered overvalued.

Omnicell has a net margin of -39.96% compared to Premier's net margin of 5.16%. Premier's return on equity of -0.24% beat Omnicell's return on equity of 1.04%.

Premier has a consensus price target of $19.79, signalling upside risk potential of 2.41%. On the other hand Omnicell has an analysts' consensus of $50.71 which suggests that it could grow by 71.04%. Given that Omnicell has higher upside potential than Premier, analysts believe Omnicell is more attractive than Premier.

Premier has a beta of 0.516, which suggesting that the stock is 48.448% less volatile than S&P 500. In comparison Omnicell has a beta of 0.785, suggesting its less volatile than the S&P 500 by 21.543%.

Premier has a quarterly dividend of $0.21 per share corresponding to a yield of 4.35%. Omnicell offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Premier pays 79.64% of its earnings as a dividend. Omnicell pays out -- of its earnings as a dividend. Premier's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Premier quarterly revenues are $240.3M, which are smaller than Omnicell quarterly revenues of $306.9M. Premier's net income of -$96M is lower than Omnicell's net income of $15.8M. Notably, Premier's price-to-earnings ratio is 14.37x while Omnicell's PE ratio is 109.81x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Premier is 1.69x versus 1.24x for Omnicell. Usually stocks with elevated PS ratios are considered overvalued.

Phreesia has a net margin of -39.96% compared to Premier's net margin of -5.83%. Premier's return on equity of -0.24% beat Phreesia's return on equity of -22.95%.

Premier has a consensus price target of $19.79, signalling upside risk potential of 2.41%. On the other hand Phreesia has an analysts' consensus of $31.77 which suggests that it could grow by 36.64%. Given that Phreesia has higher upside potential than Premier, analysts believe Phreesia is more attractive than Premier.

Premier has a beta of 0.516, which suggesting that the stock is 48.448% less volatile than S&P 500. In comparison Phreesia has a beta of 0.823, suggesting its less volatile than the S&P 500 by 17.706%.

Premier has a quarterly dividend of $0.21 per share corresponding to a yield of 4.35%. Phreesia offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Premier pays 79.64% of its earnings as a dividend. Phreesia pays out -- of its earnings as a dividend. Premier's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Premier quarterly revenues are $240.3M, which are larger than Phreesia quarterly revenues of $109.7M. Premier's net income of -$96M is lower than Phreesia's net income of -$6.4M. Notably, Premier's price-to-earnings ratio is 14.37x while Phreesia's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Premier is 1.69x versus 3.19x for Phreesia. Usually stocks with elevated PS ratios are considered overvalued.